4DMT Announces New Employment Inducement Grants

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT) announced that on April 14, 2026 its compensation committee granted a total of 67,600 Restricted Stock Units (RSUs) to five new non-executive employees under the company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).

The grants were made to induce new employees to join the company and were issued under the amended inducement plan.

Argus Apr 20 session

-4.00% close to close Open Argus

Details

News Market Reaction – FDMT

On Apr 20, the first trading day after this news, FDMT closed 4.00% below the previous close.

Data tracked by StockTitan Argus for the Apr 20 session.

Key Figures

RSUs granted: 67,600 RSUs Employees receiving RSUs: 5 employees Plan year: 2025 +1 more

RSUs granted

67,600 RSUs

Granted to five new non-executive employees on April 14, 2026

Employees receiving RSUs

5 employees

New non-executive hires under inducement plan

Plan year

2025

2025 Employment Inducement Award Plan

Nasdaq rule

Rule 5635(c)(4)

Basis for inducement equity grants

Historical Context

5 past events · Latest: Mar 18

5 events

1. Mar 18

   Earnings and pipeline

   24h Move

   +4.9%

   Full-year 2025 results, strong cash, and Otsuka collaboration upfront payment.

2. Mar 16

   Investor conferences

   24h Move

   +2.3%

   Participation in March 2026 investor meetings and conferences.

3. Feb 19

   Investor conferences

   24h Move

   +0.0%

   Announcements of multiple March 2026 healthcare conference presentations.

4. Feb 13

   Inducement grants

   24h Move

   +1.4%

   Granting 124,200 RSUs to nine new employees under inducement plan.

5. Feb 09

   Clinical milestone

   24h Move

   +1.0%

   Completion of enrollment for 4FRONT-1 Phase 3 trial of 4D-150.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, rsus, employment inducement award plan, nasdaq global market, +1 more

5 terms

restricted stock units financial

"granted five new non-executive employees 67,600 Restricted Stock Units (RSUs)."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"granted five new non-executive employees 67,600 Restricted Stock Units (RSUs)."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

employment inducement award plan financial

"granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended,"

An employment inducement award plan is a company program that grants stock, stock options, or other equity-based incentives to recruit or retain a specific new employee, similar to offering a signing bonus but paid in company shares. Investors watch these plans because they can dilute existing ownership, change management incentives, and increase compensation expense, all of which can affect share value and future company performance.

nasdaq global market regulatory

"under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants"

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

equity grants financial

"for equity grants to induce new employees to enter into employment"

Equity grants are awards of company stock or rights to buy stock given to employees, executives, or advisors as part of compensation. They matter to investors because they align employee incentives with company performance and can change the value of existing shares—similar to giving extra slices of a pie, which can reduce each current owner’s portion and affect metrics like earnings per share and shareholder returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 14, 2026, the compensation committee of the Company’s board of directors granted five new non-executive employees 67,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What RSU grants did 4D Molecular Therapeutics (FDMT) announce on April 17, 2026?

They announced a grant of 67,600 RSUs to five new non-executive employees. According to the company, the awards were granted on April 14, 2026 under the 2025 Employment Inducement Award Plan to recruit new hires.

Why did FDMT use the 2025 Employment Inducement Award Plan for these April 2026 RSUs?

FDMT used the inducement plan to grant equity to new hires under Nasdaq Rule 5635(c)(4). According to the company, this allows equity awards specifically designed to attract and retain incoming employees.

How many employees received RSUs in the FDMT April 2026 inducement grant?

Five new non-executive employees received RSUs in this grant. According to the company, the total award across those five employees amounted to 67,600 Restricted Stock Units granted on April 14, 2026.

Does the April 14, 2026 FDMT RSU grant require Nasdaq approval under Rule 5635(c)(4)?

The grant was made pursuant to Nasdaq Rule 5635(c)(4) for inducement awards, which permits certain equity grants to new employees. According to the company, the awards were issued under its amended 2025 Employment Inducement Award Plan.

Will the FDMT April 2026 RSU awards likely dilute existing shareholders?

The company granted 67,600 RSUs, which represent potential future share issuance but no dilution metric was given. According to the company, the awards were issued as inducement grants; dilution impact would depend on future vesting and outstanding share count.